GILEAD SCIENCES, INC. is 5.3x more valuable than BIOGEN INC. by market capitalization ($151.05 B vs $28.68 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BIIB | GILD |
|---|---|---|
| Market cap | $28.68 B | $151.05 B |
| US-listed rank | #476 | #99 |
| Revenue (latest FY) | $9.89B | $29.44B |
| Net income (latest FY) | $1.29B | $8.51B |
| Net margin | 13.1% | 28.9% |
| P/E (trailing FY) | 22.2 | 17.7 |
| SEC filings | 2,690 | 981 |
GILEAD SCIENCES, INC. is 5.3x more valuable than BIOGEN INC. by market capitalization ($151.05 B vs $28.68 B).
In their latest fiscal years, BIOGEN INC. reported $9.89B in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: BIOGEN INC. and GILEAD SCIENCES, INC., or browse the full rankings.